Randomized Double-Blind Placebo-Controlled Parallel-Group Study to Assess the Safety Tolerability and Efficacy of BIIB092 in Subjects with Mild Cognitive Impairment due to Alzheimer's Disease or with Mild Alzheimer's Disease
Brief description of study
The purpose of this study is to evaluate the safety and effectiveness of an experimental drug called BIIB092 as a possible treatment to slow down disease progression in subjects with mild Alzheimer' s disease. An experimental drug is one that is being tested and is not approved by the United States Food and Drug Administration (FDA). BIIB092 is not approved to treat the condition. Researchers want to find out if BIIB092 will stimulate the immune system to stop the spreading of tau from one cell to the next, possibly slowing the progress of the disease. BIIB092 will be compared to placebo to find out more about BIIB092. Placebo looks like BIIB092 but has no drug or active ingredient in it. In this form, both BIIB092 and placebo will be called study drug.
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.